AGL 5.27 Decreased By ▼ -0.23 (-4.18%)
ANL 8.45 Decreased By ▼ -0.04 (-0.47%)
AVN 75.82 Increased By ▲ 0.02 (0.03%)
BOP 5.15 Decreased By ▼ -0.09 (-1.72%)
CNERGY 4.41 Decreased By ▼ -0.01 (-0.23%)
EFERT 81.30 Decreased By ▼ -0.33 (-0.4%)
EPCL 49.29 Decreased By ▼ -0.41 (-0.82%)
FCCL 12.40 Decreased By ▼ -0.39 (-3.05%)
FFL 5.51 Increased By ▲ 0.01 (0.18%)
FLYNG 6.82 Increased By ▲ 0.09 (1.34%)
FNEL 4.68 Decreased By ▼ -0.02 (-0.43%)
GGGL 9.27 Increased By ▲ 0.85 (10.1%)
GGL 14.88 Increased By ▲ 0.93 (6.67%)
HUMNL 6.18 Increased By ▲ 0.10 (1.64%)
KEL 2.57 Increased By ▲ 0.01 (0.39%)
LOTCHEM 27.73 Increased By ▲ 0.08 (0.29%)
MLCF 23.57 Decreased By ▼ -0.22 (-0.92%)
OGDC 71.91 Increased By ▲ 0.81 (1.14%)
PAEL 15.13 Increased By ▲ 0.10 (0.67%)
PIBTL 4.83 Decreased By ▼ -0.07 (-1.43%)
PRL 15.66 Decreased By ▼ -0.32 (-2%)
SILK 1.07 Decreased By ▼ -0.03 (-2.73%)
TELE 8.85 Increased By ▲ 0.03 (0.34%)
TPL 7.34 Increased By ▲ 0.26 (3.67%)
TPLP 19.49 Increased By ▲ 0.23 (1.19%)
TREET 21.08 Increased By ▲ 0.23 (1.1%)
TRG 137.25 Increased By ▲ 0.65 (0.48%)
UNITY 16.30 Decreased By ▼ -0.25 (-1.51%)
WAVES 9.35 Increased By ▲ 0.10 (1.08%)
WTL 1.38 Increased By ▲ 0.03 (2.22%)
BR100 4,164 Increased By 6.3 (0.15%)
BR30 15,350 Increased By 10.3 (0.07%)
KSE100 41,698 Increased By 46.7 (0.11%)
KSE30 15,402 Increased By 22.3 (0.15%)
Follow us

BEIJING: Sinovac Biotech said on Saturday that its unit's COVID-19 vaccine has been approved for use by the general public by China's medical products regulator.

It marks the second vaccine approved for public use in China, after one developed by a Beijing institute affiliated with state-owned China National Pharmaceutical Group (Sinopharm) was approved in December.

Both vaccines, as well as a third candidate from Sinopharm, have already been used in China's vaccination program which has administered over 31 million doses, mainly targeting groups at higher infection risk. A fourth candidate from CanSino Biologics is being used among military personnel.

Indonesia, Turkey, Brazil, Chile, Colombia, Uruguay, and Laos have granted emergency authorisation for the CoronaVac vaccine developed by Sinovac Life Sciences, Sinovac said in a news release.

Approval of the two-dose regimen by China's National Medical Products Administration is based on results from two months of late-stage clinical trials overseas, from which the final analysis data has not yet been obtained, Sinovac said.

Its Beijing-based unit Sinovac Life Sciences is expected to be able to produce over 1 billion doses per year in the form of bulk ingredient by February, it said.

Sinovac is also expanding its capacity to fill vaccine into vials and syringes, which currently lags its vaccine manufacturing capacity. It has also outsourced filling and finishing procedures to overseas partners.

China plans to provide 10 million vaccine doses to COVAX, a World Health Organization-backed global vaccine-sharing initiative that Sinovac, Sinopharm and CanSino have applied to join, the foreign ministry has said.

A Phase I and II trial in China showed the vaccine could safely trigger immune response for older participants and it is also being tested in participants aged three to 17.

Sinovac cautioned, however, that data for the protection rate among people aged 60 and above was "limited".

"When the relevant institutions ...use this vaccine, the necessity of inoculating this product should be evaluated in consideration of the health status and exposure risk of this age group," it added.

Sinovac's vaccine is being tested in Phase III clinical trials in countries including Brazil, Turkey and Indonesia, where varied efficacy readings had been released separately, without sufficient details made available to public.

The vaccine was found 50.65% effective against COVID-19 disease in the Brazil trial which had recruited 12,396 medical workers older than 18 as of December 16 and recorded 253 cases, Sinovac said in a statement on Friday.

The success rate from the Turkey trial was 91.25%, local researchers said, based on a preliminary analysis of 29 cases. There was a 65.3% efficacy rate in the Indonesia trial.

Comments

Comments are closed.

China approves Sinovac Biotech vaccine for general public use

Economy: Dar, others take stock of situation

Weekly SPI inflation unchanged on average

Xi calls for oil trade in yuan

Unilateral hike in rates of SEZs’ plots disallowed

FTO orders FBR to release soybean consignments

Russia could cut oil production over West’s ‘stupid’ price cap

Oil rebounds, but still on track for biggest weekly declines

ECs: SBP further tightening data reporting mechanism

Wapda asked to shift troops from Dasu hospital

Matters adjudicated by courts: FBR maintains no data bank